9- (2- morpholinoethyl)- 2- (4- fluorophenyl)imidazo(1,2- alpha)benzimidazole
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Seizures (Absence Seizure)
01/01/2016
- " TID50 of RU-1205, diazepam, and valproate for clonic seizures were 7.9, 116.9, and 1.3 mg/kg (i.p.), respectively The chronic administration of RU-1205 (31 mg/kg, i.p., 28 days) did not lead to the development of anticonvulsant tolerance or rebound effect after discontinuation of treatment. " 01/01/2016
- " The TID50 values (the dose of anticonvulsant required to increase the PTZ seizure threshold by 50%) of RU-1205, diazepam, and valproate for my- oclonic seizures were 7.9, 120.4, and 1.2 mg/kg (i.p.), respectively. " 01/01/2016
- " Antiepileptic activity of a new derivative of benzimidazole RU-1205 was studied on the model of pentylenetetrazole-induced generalized seizures in mice. " 01/01/2016
- " We have studied the effects of acute administration of benzimidazole derivative RU-1205 (9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo(1,2-alpha)benzi- midazole), diazepam, and sodium valproate on the threshold for myoclonic and clonic seizures in response to i.v. infusion of pentylenetetrazole (PTZ) in mice. "
|
|
Related Drugs and Biologics